A. V. Pavlova
A. V. Pavlova has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra S. Asekritova
Republican Clinical Hospital No. 3; North-Eastern Federal University named after. M. K. Ammosov
3 shared publications - Dinara Evgenevna Ivanoshchuk
Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences
2 shared publications - E. S. Kylbanova
Federal State Autonomous Educational Institution of Higher Education “M.K. Ammosov Northeastern Federal University
2 shared publications A Limonova
National Medical Research Center for Therapy and Preventive Medicine
1 shared publicationA Vorobyev
Altai Regional Cardiology Dispensary
1 shared publication- A. E. Filippov
My Medical Center ; Saint Petersburg State University
1 shared publication
Latest Publications
- Open Access
- 30 December 2025
- Published by The Institute of Internal and Preventive Medicine in Ateroscleroz
- Vol. 21 (4) , 453-464
Microsomal triglyceride transfer protein: molecular genetics, functional mechanisms, and clinical significance
The aim of this work is to provide a comprehensive review of the structural and functional organization of the MTTP gene and the microsomal triglyceride transfer protein (MTP) it encodes, to characterize its pathogenic variants, and to describe the molecular mechanisms of their action. The MTP is a key regulator of lipid metabolism that is required for the assembly and secretion of apoB‑containing lipoproteins in hepatocytes and enterocytes. Biallelic pathogenic variants in MTTP cause abetalipoproteinemia, a rare life‑threatening disorder with progressive neurological and ophthalmological complications. Several common single nucleotide variants in this gene are associated with various metabolic disturbances. A literature review was conducted, including analysis of the gene structure and mechanisms of alternative splicing of MTTP , the domain organization of MTP, its interaction with protein disulfide isomerase, and selected pathogenic variants of this gene based on published functional studies and clinical data. An in‑depth understanding of the molecular mechanisms underlying MTP dysfunction is essential for accurate interpretation of genetic testing results, prediction of clinical phenotype, differential diagnosis, and the development of personalized therapeutic strategies for abetalipoproteinemia and related disorders.
- 30 December 2025
- Published by The Institute of Internal and Preventive Medicine in Ateroscleroz
- Vol. 21 (4) , 453-464
Open AccessMicrosomal triglyceride transfer protein: molecular genetics, functional mechanisms, and clinical significance
The aim of this work is to provide a comprehensive review of the structural and functional organization of the MTTP gene and the microsomal triglyceride transfer protein (MTP) it encodes, to characterize its pathogenic variants, and to describe the molecular mechanisms of their action. The MTP is a key regulator of lipid metabolism that is required for the assembly and secretion of apoB‑containing lipoproteins in hepatocytes and enterocytes. Biallelic pathogenic variants in MTTP cause abetalipoproteinemia, a rare life‑threatening disorder with progressive neurological and ophthalmological complications. Several common single nucleotide variants in this gene are associated with various metabolic disturbances. A literature review was conducted, including analysis of the gene structure and mechanisms of alternative splicing of MTTP , the domain organization of MTP, its interaction with protein disulfide isomerase, and selected pathogenic variants of this gene based on published functional studies and clinical data. An in‑depth understanding of the molecular mechanisms underlying MTP dysfunction is essential for accurate interpretation of genetic testing results, prediction of clinical phenotype, differential diagnosis, and the development of personalized therapeutic strategies for abetalipoproteinemia and related disorders.
- 30 December 2025
- Published by The Institute of Internal and Preventive Medicine in Ateroscleroz
- Vol. 21 (4)
Variants in the LDLR and the APOB genes in patients with familial hypercholesterolemia in the Republic of Sakha (Yakutia)
The aim of the study. Molecular genetic studies of familial hypercholesterolemia (FH) have been conducted in different regions of the Russian Federation for several decades. However, limited ethnic diversity in patient samples does not permit a comprehensive assessment of the full spectrum of gene variability responsible for FH development in the Russian population. The aim of this study was to characterize the molecular heterogeneity of the LDLR and APOB genes in patients with FH phenotype in the Republic of Sakha (Yakutia). Material and methods. A group of 48 patients with FH was enrolled at the Department of Lipid Disorders, Republican Clinical Hospital No. 3, Yakutsk. FH diagnosis was established using the Dutch Lipid Clinic Network (DLCN) Criteria. All patients underwent clinical examination, ultrasonographic evaluation, and blood sampling for biochemical and molecular genetic analyses. Molecular variants in index patients and segregation analysis in available family members were identified using direct automated Sanger sequencing of the LDLR gene promoter and all exons, as well as exon 26 of the APOB gene. Results. Pathogenic variants in the LDLR gene were identified in three index patients with the FH phenotype. Segregation analysis in families of index patients identified three additional carriers of the rs121908038 variant among first-degree relatives. Based on direct automated sequencing of exon 26 of the APO B gene, a pathogenic variant (rs5742904) was identified in one index patient and three of his first-degree relatives. Conclusions. Molecular genetic analysis of the LDLR gene and exon 26 of the APOB gene in patients with the FH phenotype from the Republic of Sakha (Yakutia) identified pathogenic variants in two genes. Heterozygous familial hypercholesterolemia was confirmed in index patients and segregated among first-degree relatives. These findings underscore the importance of genetic testing and family screening in FH diagnosis and management.
- 30 December 2025
- Published by The Institute of Internal and Preventive Medicine in Ateroscleroz
- Vol. 21 (4)
Variants in the LDLR and the APOB genes in patients with familial hypercholesterolemia in the Republic of Sakha (Yakutia)
The aim of the study. Molecular genetic studies of familial hypercholesterolemia (FH) have been conducted in different regions of the Russian Federation for several decades. However, limited ethnic diversity in patient samples does not permit a comprehensive assessment of the full spectrum of gene variability responsible for FH development in the Russian population. The aim of this study was to characterize the molecular heterogeneity of the LDLR and APOB genes in patients with FH phenotype in the Republic of Sakha (Yakutia). Material and methods. A group of 48 patients with FH was enrolled at the Department of Lipid Disorders, Republican Clinical Hospital No. 3, Yakutsk. FH diagnosis was established using the Dutch Lipid Clinic Network (DLCN) Criteria. All patients underwent clinical examination, ultrasonographic evaluation, and blood sampling for biochemical and molecular genetic analyses. Molecular variants in index patients and segregation analysis in available family members were identified using direct automated Sanger sequencing of the LDLR gene promoter and all exons, as well as exon 26 of the APOB gene. Results. Pathogenic variants in the LDLR gene were identified in three index patients with the FH phenotype. Segregation analysis in families of index patients identified three additional carriers of the rs121908038 variant among first-degree relatives. Based on direct automated sequencing of exon 26 of the APO B gene, a pathogenic variant (rs5742904) was identified in one index patient and three of his first-degree relatives. Conclusions. Molecular genetic analysis of the LDLR gene and exon 26 of the APOB gene in patients with the FH phenotype from the Republic of Sakha (Yakutia) identified pathogenic variants in two genes. Heterozygous familial hypercholesterolemia was confirmed in index patients and segregated among first-degree relatives. These findings underscore the importance of genetic testing and family screening in FH diagnosis and management.
- Open Access
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 244-256
Effectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.
- 22 August 2025
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 21 (3) , 244-256
Open AccessEffectiveness of fixed-dose combination of rosuvastatin and ezetimibe in heterozygous familial hypercholesterolemia from the RENAISSANCE registry
Aim. To study the adequacy and effectiveness of lipid-lowering therapy (LLT) prescribed to patients with heterozygous familial hypercholesterolemia (HeFH), including fixed-dose combinations (FDC) of rosuvastatin with ezetimibe, as well as the frequency of achieving target low-density lipoprotein cholesterol (LDL-C) levels.Material and methods. The clinical and demographic data of 3151 patients with HeFH at high or very high cardiovascular risk from the RENAISSANCE registry were retrospectively analysed. Among the 1612 individuals receiving LLT, 477 patients were treated with a combination of rosuvastatin at various doses and ezetimibe 10 mg daily, either as a free combination or as a FDC.Results. The median age of the patients was 46.0 [32.0; 57.0] years. The median LDL-C level was 6.4 [5.3; 7.8] mmol/L. Although LLT was recommended to all participants, approximately half (49%, n=1539) were not receiving treatment. Among the 1612 patients on LLT, 44% (n=703) received statin monotherapy, and 43% (n=697) were treated with a combination of statins and ezetimibe. Of the 477 patients taking rosuvastatin with ezetimibe, the majority were active adults of working age (35-64 years): 335 (80%) vs 86 (20%), p Conclusion. Among patients with НeFH, the use of a FDC of rosuvastatin and ezetimibe is associated with higher treatment adherence and a greater likelihood of achieving target LDL-С levels.